Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients.

Buysschaert M, D'Hooge D, Preumont V; Roots Study Group..

Diabetes Metab Syndr. 2015 Jul-Sep;9(3):139-42. doi: 10.1016/j.dsx.2015.05.001. Epub 2015 May 8.

PMID:
26004030
2.

In antibody-positive first-degree relatives of patients with type 1 diabetes, HLA-A*24 and HLA-B*18, but not HLA-B*39, are predictors of impending diabetes with distinct HLA-DQ interactions.

Mbunwe E, Van der Auwera BJ, Weets I, Van Crombrugge P, Crenier L, Coeckelberghs M, Seret N, Decochez K, Vandemeulebroucke E, Gillard P, Keymeulen B, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers DG, Gorus FK; Belgian Diabetes Registry..

Diabetologia. 2013 Sep;56(9):1964-70. doi: 10.1007/s00125-013-2951-8. Epub 2013 May 28.

3.

HLA-A*24 is an independent predictor of 5-year progression to diabetes in autoantibody-positive first-degree relatives of type 1 diabetic patients.

Mbunwe E, Van der Auwera BJ, Vermeulen I, Demeester S, Van Dalem A, Balti EV, Van Aken S, Derdelinckx L, Dorchy H, De Schepper J, van Schravendijk C, Wenzlau JM, Hutton JC, Pipeleers D, Weets I, Gorus FK; Belgian Diabetes Registry..

Diabetes. 2013 Apr;62(4):1345-50. doi: 10.2337/db12-0747. Epub 2012 Nov 16.

4.

Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.

Mathieu C, Robbrecht S.

Diabetes Obes Metab. 2008 Jul;10 Suppl 2:14-23. doi: 10.1111/j.1463-1326.2008.00841.x.

PMID:
18577153

Supplemental Content

Loading ...
Support Center